Clinical Trials Browser

Not yet recruiting × Triple Negative Breast Neoplasms × camrelizumab × Clear all

NCT06731153 2024-12-12

JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC

Phase 2 Not yet recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms